Developer docs
API playgroundTry for free, no card

Search company profiles

Terrapeutics Pharma

Full company profile

uuid0003rag

Namestring
Terrapeutics Pharma
Legal namestring
Terrapeutics
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Terrapeutics Pharma is a privately-held Israeli biotech founded in 2019 and headquartered in Jerusalem, operating with 1-10 employees. The company has built a drug discovery platform that screens naturally evolved molecular scaffolds produced by soil microorganisms against therapeutic targets that conventional synthetic chemistry-based discovery cannot reach. The platform specifically targets classes historically considered 'undruggable,' including protein-protein interactions, non-steroidal transcription factors, and nucleic acid complexes, with current pipeline focus on RAS inhibitors for cancer and novel antibiotics for infectious disease.

The company's core technology exploits what it estimates is 99.9% of nature's therapeutic potential that current discovery methodologies fail to access, leveraging scaffolds developed through 4 billion years of microbial evolution. Validation is anchored by a co-development agreement with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) in Germany for joint work on antibiotics and RAS inhibitors, and a partnership with HekaBio K.K. to bring the platform to the Japanese market. Selection into Illumina Accelerator's fifth global funding cycle provides additional third-party endorsement of the underlying science.

Terrapeutics operates a B2B licensing and partnership-driven model, monetizing through co-development agreements and platform licensing to pharmaceutical and biotechnology counterparties rather than through direct product sales. The company has raised approximately $1.39M across two Peregrine Ventures rounds in 2024 and 2025, supplemented by an in-kind Illumina Accelerator investment. Pricing is not publicly disclosed and appears to be negotiated per partnership or per license. As of the available data, no commercial licensing transactions have been announced, and the company remains in pre-revenue platform validation phase.

Short descriptiontext

Terrapeutics Pharma is an Israel-based biotech using soil microorganism-derived molecular scaffolds to discover drugs against 'undruggable' targets such as RAS-driven cancers and antibiotic-resistant infections, licensing its platform to pharmaceutical partners through co-development agreements.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersAlameda, United States
HQ citystring
Alameda
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
drug discovery platform, nature-derived therapeutics, RAS inhibitor discovery, soil microorganism screening, undruggable target discovery
Industry2 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical and Medicine Manufacturing3254
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Biological Products, (No Disgnostic Substances)2836
Product category
Drug Discovery Services
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Drug Discovery Platform Licensing
TypeLicensing Royalties
Description

Revenue model appears to be licensing the proprietary drug discovery platform technology to pharmaceutical companies. The company discovers and develops molecules for challenging targets (RAS inhibitors, antibiotics) and likely licenses these candidates or the platform technology to larger pharma companies for further development and commercialization.

terrapeuticspharma.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Terrapeutics Pharma operates a proprietary drug discovery platform that screens molecular scaffolds produced by soil microorganisms to identify therapeutic candidates against targets considered "undruggable" by conventional synthetic chemistry approaches. Current therapeutic focus areas include RAS inhibitors for cancer and novel antibiotics for infectious diseases, with candidates advanced through licensing and co-development agreements with pharmaceutical partners.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Terrapeutics Pharma operates as a single-platform drug discovery company offering its proprietary drug discovery platform. This unified platform enables the screening of nature-derived therapeutic molecules against challenging and previously 'undruggable' drug targets. The company's current therapeutic focus areas include RAS inhibitors for cancer treatment and infectious diseases, with plans to expand to additional undruggable targets.

Product and service1 record
1Terrapeutics Drug Discovery Platform
Scale indicator1 record

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Terrapeutics Pharma partnered with HekaBio K.K. to bring their revolutionary drug discovery platform to Japan. This partnership enables geographic expansion into the Japanese pharmaceutical market.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Terrapeutics signed a cooperation agreement with HIPS for the joint development of novel bioactive compounds including antibiotics and RAS inhibitors for the treatment of incurable cancers. This represents a major co-development partnership for pipeline advancement.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Insitro combines machine learning with high-throughput biology to discover therapeutics for challenging diseases. It is a broader incumbent whose partnership-driven business model closely parallels Terrapeutics' GTM motion, although its biology-first platform differs in modality.

TypeEmerging player
Description

Atomwise applies AI to small-molecule discovery against challenging protein targets, with a partnership-heavy model analogous to Terrapeutics'. It is an emerging player in the 'undruggable target' space where both compete for the same pharma partner mindshare.

TypeBroad incumbent
Description

Schrödinger provides computational drug discovery software and services that increasingly enable screening of novel chemical spaces. It competes with nature-derived approaches by offering in silico alternatives for difficult targets and partners with many of the same pharma companies.

TypeBroad incumbent
Description

Generate Biomedicines uses generative AI to design novel protein therapeutics, representing a broader incumbent addressing the same 'undruggable' target problem from a synthetic-biology angle. It competes for pharma partnership dollars focused on novel target classes.

TypeDirect peer
Description

Hexagon Bio is a US-based drug discovery company that mines fungal genomes for novel therapeutics, making it the closest direct peer to Terrapeutics' soil-microorganism screening approach. Both target nature-derived chemical diversity to address difficult drug targets.

TypeEmerging player
Description

Antheia uses synthetic biology to produce plant-derived and opioid pharmaceuticals from engineered microbes. It is an emerging player adjacent to Terrapeutics in leveraging biological platforms to access hard-to-make therapeutic molecules.

TypeBroad incumbent
Description

Recursion applies AI-driven high-throughput biology to drug discovery, competing for partnerships with pharma seeking novel approaches to challenging targets. While broader in scope, it competes for the same licensing and co-development mindshare among large pharma partners.

TypeDirect peer
Description

Lodo Therapeutics (acquired by Zymergen) applied microbial metagenomics and machine learning to identify novel drug candidates from soil bacteria, directly mirroring Terrapeutics' nature-derived discovery thesis. It represents an early comparable for the soil-microbe drug discovery business model.

9Federation Bio
TypeEmerging player
Description

Federation Bio engineers microbiome-derived therapeutics, with overlapping interest in microbial chemistry and synthetic biology approaches. It is an emerging player in the broader nature-derived therapeutic space with partial overlap in undruggable target strategies.

TypeBroad incumbent
Description

Revolution Medicines is a clinical-stage oncology company developing RAS(ON) inhibitors, directly addressing the same RAS target class that Terrapeutics highlights as a current focus. It is a broader incumbent setting the competitive bar in the same therapeutic area.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Terrapeutics Pharma

Drug Discovery Servicesterrapeuticspharma.com

Terrapeutics Pharma is an Israel-based biotech using soil microorganism-derived molecular scaffolds to discover drugs against 'undruggable' targets such as RAS-driven cancers and antibiotic-resistant infections, licensing its platform to pharmaceutical partners through co-development agreements.

What Terrapeutics Pharma does

Terrapeutics Pharma is a privately-held Israeli biotech founded in 2019 and headquartered in Jerusalem, operating with 1-10 employees. The company has built a drug discovery platform that screens naturally evolved molecular scaffolds produced by soil microorganisms against therapeutic targets that conventional synthetic chemistry-based discovery cannot reach. The platform specifically targets classes historically considered 'undruggable,' including protein-protein interactions, non-steroidal transcription factors, and nucleic acid complexes, with current pipeline focus on RAS inhibitors for cancer and novel antibiotics for infectious disease.

The company's core technology exploits what it estimates is 99.9% of nature's therapeutic potential that current discovery methodologies fail to access, leveraging scaffolds developed through 4 billion years of microbial evolution. Validation is anchored by a co-development agreement with the Helmholtz Institute for Pharmaceutical Research Saarland (HIPS) in Germany for joint work on antibiotics and RAS inhibitors, and a partnership with HekaBio K.K. to bring the platform to the Japanese market. Selection into Illumina Accelerator's fifth global funding cycle provides additional third-party endorsement of the underlying science.

Terrapeutics operates a B2B licensing and partnership-driven model, monetizing through co-development agreements and platform licensing to pharmaceutical and biotechnology counterparties rather than through direct product sales. The company has raised approximately $1.39M across two Peregrine Ventures rounds in 2024 and 2025, supplemented by an in-kind Illumina Accelerator investment. Pricing is not publicly disclosed and appears to be negotiated per partnership or per license. As of the available data, no commercial licensing transactions have been announced, and the company remains in pre-revenue platform validation phase.

Terrapeutics Pharma firmographics

Firmographics
Name
Terrapeutics Pharma
Legal name
Terrapeutics
Website
https://terrapeuticspharma.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
1–10 employees
Short description
Terrapeutics Pharma is an Israel-based biotech using soil microorganism-derived molecular scaffolds to discover drugs against 'undruggable' targets such as RAS-driven cancers and antibiotic-resistant infections, licensing its platform to pharmaceutical partners through co-development agreements.
Ownership category
akta.pro rank

Terrapeutics Pharma industry classification

Industry
Product category
Drug Discovery Services
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Drug discovery platform
  • Nature-derived therapeutics
  • RAS inhibitor discovery
  • Soil microorganism screening
  • Undruggable target discovery

Where Terrapeutics Pharma is headquartered

Location

Headquarters

HQ city
Alameda
HQ country
United States
HQ region
North America

Markets served

Terrapeutics Pharma business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Discovery Platform Licensing: Revenue model appears to be licensing the proprietary drug discovery platform technology to pharmaceutical companies. The company discovers and develops molecules for challenging targets (RAS inhibitors, antibiotics) and likely licenses these candidates or the platform technology to larger pharma companies for further development and commercialization.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Terrapeutics Pharma product offering

Product offering

Core offering

Terrapeutics Pharma operates a proprietary drug discovery platform that screens molecular scaffolds produced by soil microorganisms to identify therapeutic candidates against targets considered "undruggable" by conventional synthetic chemistry approaches. Current therapeutic focus areas include RAS inhibitors for cancer and novel antibiotics for infectious diseases, with candidates advanced through licensing and co-development agreements with pharmaceutical partners.

Product overview

Terrapeutics Pharma operates as a single-platform drug discovery company offering its proprietary drug discovery platform. This unified platform enables the screening of nature-derived therapeutic molecules against challenging and previously 'undruggable' drug targets. The company's current therapeutic focus areas include RAS inhibitors for cancer treatment and infectious diseases, with plans to expand to additional undruggable targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • Terrapeutics Drug Discovery Platform

Companies that use Terrapeutics Pharma

Customer profile

Segments2 records

Ideal customer profiles1 record

Terrapeutics Pharma technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Terrapeutics Pharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • HekaBio K.K.coreStrategic or Co-development PartnerTerrapeutics Pharma partnered with HekaBio K.K. to bring their revolutionary drug discovery platform to Japan. This partnership enables geographic expansion into the Japanese pharmaceutical market.
  • HIPS (Helmholtz Institute for Pharmaceutical Research Saarland)coreStrategic or Co-development PartnerTerrapeutics signed a cooperation agreement with HIPS for the joint development of novel bioactive compounds including antibiotics and RAS inhibitors for the treatment of incurable cancers. This represents a major co-development partnership for pipeline advancement.

Scale indicators1 record

Recent moves5 records

Expansion highlights4 records

Terrapeutics Pharma competitors and assessment

Company assessment

Broad incumbents

  • Insitro: Insitro combines machine learning with high-throughput biology to discover therapeutics for challenging diseases. It is a broader incumbent whose partnership-driven business model closely parallels Terrapeutics' GTM motion, although its biology-first platform differs in modality.
  • Schrödinger Inc. Schrödinger provides computational drug discovery software and services that increasingly enable screening of novel chemical spaces. It competes with nature-derived approaches by offering in silico alternatives for difficult targets and partners with many of the same pharma companies.
  • Generate Biomedicines: Generate Biomedicines uses generative AI to design novel protein therapeutics, representing a broader incumbent addressing the same 'undruggable' target problem from a synthetic-biology angle. It competes for pharma partnership dollars focused on novel target classes.
  • Recursion Pharmaceuticals: Recursion applies AI-driven high-throughput biology to drug discovery, competing for partnerships with pharma seeking novel approaches to challenging targets. While broader in scope, it competes for the same licensing and co-development mindshare among large pharma partners.
  • Revolution Medicines: Revolution Medicines is a clinical-stage oncology company developing RAS(ON) inhibitors, directly addressing the same RAS target class that Terrapeutics highlights as a current focus. It is a broader incumbent setting the competitive bar in the same therapeutic area.

Emerging players

  • Atomwise: Atomwise applies AI to small-molecule discovery against challenging protein targets, with a partnership-heavy model analogous to Terrapeutics'. It is an emerging player in the 'undruggable target' space where both compete for the same pharma partner mindshare.
  • Antheia: Antheia uses synthetic biology to produce plant-derived and opioid pharmaceuticals from engineered microbes. It is an emerging player adjacent to Terrapeutics in leveraging biological platforms to access hard-to-make therapeutic molecules.
  • Federation Bio: Federation Bio engineers microbiome-derived therapeutics, with overlapping interest in microbial chemistry and synthetic biology approaches. It is an emerging player in the broader nature-derived therapeutic space with partial overlap in undruggable target strategies.

Direct peers

  • Hexagon Bio: Hexagon Bio is a US-based drug discovery company that mines fungal genomes for novel therapeutics, making it the closest direct peer to Terrapeutics' soil-microorganism screening approach. Both target nature-derived chemical diversity to address difficult drug targets.
  • Lodo Therapeutics: Lodo Therapeutics (acquired by Zymergen) applied microbial metagenomics and machine learning to identify novel drug candidates from soil bacteria, directly mirroring Terrapeutics' nature-derived discovery thesis. It represents an early comparable for the soil-microbe drug discovery business model.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

Terrapeutics Pharma social profiles

Digital presence

Terrapeutics Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Terrapeutics Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Terrapeutics Pharma funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Terrapeutics Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Terrapeutics Pharma

What does Terrapeutics Pharma do?

Terrapeutics Pharma operates a proprietary drug discovery platform that screens molecular scaffolds produced by soil microorganisms to identify therapeutic candidates against targets considered "undruggable" by conventional synthetic chemistry approaches. Current therapeutic focus areas include RAS inhibitors for cancer and novel antibiotics for infectious diseases, with candidates advanced through licensing and co-development agreements with pharmaceutical partners.

Is Terrapeutics Pharma a public or private company?

Terrapeutics Pharma is a private company. It is classified as venture growth investor backed and is currently operating.

When was Terrapeutics Pharma founded?

Terrapeutics Pharma was founded in 2019. It employs 1 to 10 people.

Where is Terrapeutics Pharma based?

Terrapeutics Pharma is headquartered in Alameda, United States, in the North America region.

How does Terrapeutics Pharma make money?

One revenue line is on record: drug Discovery Platform Licensing.

Who are Terrapeutics Pharma's main competitors?

Broad incumbents on record are Insitro, Schrödinger Inc., Generate Biomedicines, Recursion Pharmaceuticals and Revolution Medicines. Emerging players are Atomwise, Antheia and Federation Bio. Direct peers are Hexagon Bio and Lodo Therapeutics.

Does Terrapeutics Pharma have an API?

No public API is recorded for Terrapeutics Pharma.

What industry is Terrapeutics Pharma in?

Terrapeutics Pharma's product category is Drug Discovery Services. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales